Regulatory

31. How Biopharmas Can Navigate Data Privacy Laws And Unlock Value 4/3/2023

    It should be no surprise that data privacy and responsibility is emerging as a high-priority target for life sciences companies, driven by regulatory compliance and market differentiation.

32. A Regulator Looks Back On What We Learned From Accelerated SARS-CoV-2 Neutralizing mAbs Development 3/29/2023

    Prior knowledge, platforms, parallel backup programs, and strategic timing all come into play when rapidly scaling up a mAbs development program in response to a public health emergency.

33. Draft FDA Labeling Guidance Proposes More Clarity For Providers 3/7/2023

    The FDA's draft guidance for prescription and biologic drugs updates a 2010 guidance and comes following the boom of activity in the biologics space. This article breaks down and analyzes the update on labeling for prescription drugs and biologics on an increasingly complex landscape. 

34. Circumstances For Delaying, Denying, Limiting, Or Refusing An FDA Inspection 3/1/2023

    Delaying, denying, limiting, or refusing a drug or device inspection without a reasonable justification will result in a less than collegial atmosphere during an FDA inspection.

35. Trends In FDA FY2022 Inspection-Based Warning Letters 2/21/2023

    We analyzed the warning letters that the FDA issued to pharmaceutical and biotech companies in FY2022. Several key trends emerged, including a heightened scrutiny on two product types.

36. 2023's Market Outlook For Cell And Gene Therapies 2/14/2023

    This article discusses quantifiable market trends, clinical developments, regulatory landscape analysis, and investment trends for cell and gene therapy companies in 2023.

37. Persistent Noncompliance Leads To A Consent Decree 2/1/2023

    What happens when failures are discovered repeatedly during FDA inspections, even after the company has been warned to correct them?

38. The Modernization Of Life Sciences RIM 2/1/2023

    A decade since we started tracking their ambitions for improving global regulatory information management (RIM), life science regulatory operations have achieved much in modernizing the immediate function globally and improving general operational efficiency.

39. 5 Steps To Eliminate Weak Links In Your Data Governance 12/2/2022

    Major regulators including the FDA and EMA have established frameworks through which data must be captured and exchanged with them. But your pharma, biotech, or medical device company needs a solid plan for how that data will be governed.

40. FDA Releases Guidance On Drug Products Containing Nanomaterials 11/18/2022

    In the FDA guidance entitled Drug Products, Including Biological Products, that Contain Nanomaterials, “nanomedicine” refers to a drug product that contains at least one component with a dimension in the size range of approximately 1 nanometer (nm) up to 100 nm. Focus of the guidance is on a risk-based regulatory strategy.